Tripos Names New VP of Business Development and Strategic Alliances, Discovery Research
News Dec 16, 2005
Tripos, Inc. has announced that it has appointed Dr. Tom Mander as vice president of business development and strategic alliances, Discovery Research.
In his new role, Mander will be responsible for identifying new business development opportunities, establishing strategic alliances, developing intellectual property, and driving marketing initiatives for Tripos Discovery Research, Ltd. (TDR), which is located in Bude, England.
"Tom possesses an ideal blend of scientific expertise, leadership skills and international business development experience that will contribute to TDR’s continued evolution," said Dr. Mark Allen, senior vice president and managing director of TDR.
Mander brings 13 years of experience in small molecule drug discovery to Tripos. For the past six and a half years, Mander has held a variety of operational and commercial roles at Evotec, including department manager, product manager and vice president of business development.
He is credited with pioneering Evotec’s biological service offerings, launching several new products lines including Compound Management, establishing new strategic partnerships, and creating new business models.
Before joining Evotec, Mander was a group leader at Glaxo Wellcome, and held senior scientific roles at Xenova Ltd., the Centre for Natural Product Research (now MerLion) and Amersham International (now GE Healthcare).
"I am delighted to have joined Tripos Discovery Research," Mander said.
"It has established an unsurpassed level of expertise in high throughput parallel and analytical chemistry in a truly unique location conducive to innovation and creativity on behalf of its partners."
"I am looking forward to utilizing my experience to drive the company forward as we begin a new era at Tripos."
Mander holds a Doctor of Philosophy degree in a study of the physiological roles of microglia (brain macrophages) from the University of Oxford, a master of business administration degree from the Open University, and a bachelor’s degree in medical biochemistry from the School of Biological Sciences at the University of Surrey.
Researchers at the Crick and Imperial College London have generated malaria parasites resistant to a promising new class of candidate antimalarial drugs. By analyzing the structural changes behind the resistance, they identified novel compounds that were immune to this mechanism of resistance.READ MORE